Letters to the Editor

Incidence of Newly Detected Atrial Arrhythmias Through Implantable Devices in Patients With a History of Thrombembolic Events

To the Editor:
I read the article by Ziegler et al,1 and their results are an important addition to the literature on the high detection rate of paroxysmal atrial fibrillation (AF) in patients with cryptogenic stroke. I have some concern, however, about some of the definitions the authors used, particularly on the duration of AF. The authors cite a report from the Heart Rhythm Society (HRS)2 about the definition of AF being >30 seconds as a justification for longer cardiac monitoring. They comment on this duration because the study by Tayal et al3 reported AF of <30 seconds using an external monitor. However, the HRS document directly refers to a consensus statement by the American College of Cardiology, which the authors could have referenced, and which also includes the following statement: “Episodes of AF briefer than 30 s may be important in certain clinical situations involving symptomatic patients, preexcitation or in assessing the effectiveness of therapeutic interventions.”4 I would argue that a patient with a prior embolic stroke would be considered symptomatic. Given the superiority of warfarin over aspirin for AF, and the equivalent safety and effectiveness of warfarin and aspirin in the Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial for cryptogenic stroke,5 the <30-second episodes may be sufficient to change management in cryptogenic strokes. The authors then use a 5-minute justification of atrial fibrillation based on results from the MOde Selection Trial (MOST) study.6 However, a 5-minute cutoff was only used for high rate atrial arrhythmias and was not used for AF; it was not AF that was associated with the outcomes mentioned in the report by Ziegler. The authors go on to advocate for prolonged monitors that are placed subcutaneously, which are incidentally also made by Medtronic (funding source for the article and employer of several of the authors), although a trial is currently underway to evaluate the effectiveness of these devices. Further statements on the role of the funding source may have been helpful. The authors indicate that the rate of detection of AF increased to 36% using a shorter time interval, but it may have been useful to see the Kaplan-Meier curves for that time window. It could be that an externally placed device may be sufficient to detect clinically important AF within 30 days.

Disclosures
None.

Joshua Z. Willey, MD, MS
Columbia University
New York, NY


Stroke welcomes Letters to the Editor and will publish them, if suitable, as space permits. They should not exceed 750 words (including references) and may be subject to editing or abridgment. Please submit letters in duplicate, typed double-spaced. Include a fax number for the corresponding author and a completed copyright transfer agreement form (available online at http://stroke.ahajournals.org and http://submit-stroke.ahajournals.org).
Incidence of Newly Detected Atrial Arrhythmias Through Implantable Devices in Patients With a History of Thromboembolic Events
Joshua Z. Willey

*Stroke*. 2010;41:e452; originally published online April 29, 2010;
doi: 10.1161/STROKEAHA.110.584250

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/41/6/e452